Literature DB >> 11105490

ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors.

P Saunderson1, S Gebre, P Byass.   

Abstract

Erythema nodosum leprosum (ENL), or type 2 leprosy reactions are an important complication of multibacillary leprosy. The AMFES cohort includes 300 new multibacillary cases that have been followed for up to 10 years from the start of treatment, in central Ethiopia. Sixteen (5.3%) patients had ENL reactions. The incidence of ENL was maximal in the second and third years after the start of treatment, reaching 6.9 episodes per 100 person years at risk. Factors associated with being lepromatous [LL classification and a high bacillary index (BI)] gave an increased risk of developing ENL; in the univariate analysis, LL classification gave a relative risk of 3.6 (95% CI 1.3-10) and a BI of 6 gave a relative risk of 8.6 (95% CI 2.3-32) for the development of ENL. HIV co-infection was found to be a risk factor in this cohort, but as the numbers involved are small (only two HIV positive patients had ENL), this finding must be confirmed in larger studies. Ten of the 16 cases had recurrent episodes and five had at least five episodes occurring over a period of more than 2 years. The management and prognosis of ENL reactions are discussed.

Entities:  

Mesh:

Year:  2000        PMID: 11105490     DOI: 10.5935/0305-7518.20000035

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  10 in total

1.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

2.  Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1 infected patient after initiation of antiretroviral therapy.

Authors:  Alexia Cusini; Huldrych F Günthard; Rainer Weber; Milo Huber; Jivko Kamarashev; Barbara Bertisch; Silke Peter; Bernhard Beck
Journal:  BMJ Case Rep       Date:  2009-12-01

3.  Case Report: A Case Series of Immunobiological Therapy (Anti-TNF-α) for Patients With Erythema Nodosum Leprosum.

Authors:  Ana Flávia Moura Mendes; Ciro Martins Gomes; Patrícia Shu Kurizky; Mayra Ianhez
Journal:  Front Med (Lausanne)       Date:  2022-06-24

4.  Understanding leprosy reactions and the impact on the lives of people affected: An exploration in two leprosy endemic countries.

Authors:  Annisa Ika Putri; Kevin de Sabbata; Regitta I Agusni; Medhi Denisa Alinda; Joydeepa Darlong; Barbara de Barros; Stephen L Walker; Marjolein B M Zweekhorst; Ruth M H Peters
Journal:  PLoS Negl Trop Dis       Date:  2022-06-13

5.  Peripheral Neuropathy Due to Leprosy.

Authors:  Sharon P. Nations; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.972

6.  Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: Two Randomised, Double Blind, Controlled Pilot Studies in Ethiopia.

Authors:  Saba M Lambert; Shimelis D Nigusse; Digafe T Alembo; Stephen L Walker; Peter G Nicholls; Munir H Idriss; Lawrence K Yamuah; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2016-02-26

7.  Drug Resistance in Mycobacterium Leprae in the Context of Zero Leprosy.

Authors:  Itu Singh; Utpal Sengupta
Journal:  Indian Dermatol Online J       Date:  2021-11-22

Review 8.  A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.

Authors:  Carlijn G N Voorend; Erik B Post
Journal:  PLoS Negl Trop Dis       Date:  2013-10-03

9.  The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study.

Authors:  Stephen L Walker; Eglantine Lebas; Shimelis N Doni; Diana N J Lockwood; Saba M Lambert
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

10.  Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports.

Authors:  Pugazhenthan Thangaraju; Sajitha Venkatesan; Meenalotchini Gurunthalingam; Shoban Babu; Tamilselvan T
Journal:  Rev Soc Bras Med Trop       Date:  2020-09-11       Impact factor: 1.581

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.